Biological Therapy for Ulcerative Colitis

Overview

Journal Gastroenterol Rep (Oxf)

Specialty Gastroenterology

Date 2014 Oct 27

PMID 25344680

Citations 21

Authors

Zubin Arora

Bo Shen

Affiliations

Soon will be listed here.

Abstract

Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD) worldwide. Better understanding of the pathogenesis of UC has led to the development of novel therapeutic agents that target specific mediators of the inflammatory cascade. A number of biological agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of UC and several more are currently in various phases of drug development. The commonly used agents include TNFα antagonists (e.g. infliximab, adalimumab, and golimumab) and anti-integrin agents (vedolizumab). These biological agents have profoundly influenced the management of UC patients, especially those with refractory disease. This paper reviews the currently available knowledge and evidence for the use of various biological agents in the treatment of UC.

Citing Articles

The Effect of the Size of Gold Nanoparticle Contrast Agents on CT Imaging of the Gastrointestinal Tract and Inflammatory Bowel Disease.

Rosario-Berrios D, Pang A, Liu L, Maidment P, Kim J, Yoon S Bioconjug Chem. 2025; 36(2):233-244.

PMID: 39786354 PMC: 11839313. DOI: 10.1021/acs.bioconjchem.4c00507.

Pharmacogenetic Effect of Thiopurine Methyl Transferase (TPMT) Gene Expression and Serum TNF on the Imuran Response in Ulcerative Colitis (UC) Iraqi Patients.

Ali N, Abdulkareem R Rep Biochem Mol Biol. 2024; 12(3):438-447.

PMID: 38618257 PMC: 11015922. DOI: 10.61186/rbmb.12.3.438.

Intestinal Inflammation and Regeneration-Interdigitating Processes Controlled by Dietary Lipids in Inflammatory Bowel Disease.

Kwon S, Khan M, Kim S Int J Mol Sci. 2024; 25(2).

PMID: 38279309 PMC: 10816399. DOI: 10.3390/ijms25021311.

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States.

Zhdanava M, Zhao R, Manceur A, Kachroo S, Lefebvre P, Pilon D Crohns Colitis 360. 2023; 5(3):otad045.

PMID: 37671391 PMC: 10476877. DOI: 10.1093/crocol/otad045.

TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases.

Zhang M, Ma Y, Ye X, Zhang N, Pan L, Wang B Signal Transduct Target Ther. 2023; 8(1):261.

PMID: 37402746 PMC: 10319900. DOI: 10.1038/s41392-023-01464-x.

References

Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R . Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007; 13(11):1323-32. DOI: 10.1002/ibd.20225. View

Yeates J, Rashid M . Successful long-term use of infliximab in refractory pouchitis in an adolescent. Gastroenterol Res Pract. 2011; 2010:860394. PMC: 3025371. DOI: 10.1155/2010/860394. View

Kaser A, Mairinger T, Vogel W, Tilg H . Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr. 2002; 113(23-24):930-3. View

Actis G, Bruno M, Pinna-Pintor M, Rossini F, Rizzetto M . Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis. 2002; 34(9):631-4. DOI: 10.1016/s1590-8658(02)80205-5. View

Danese S, Fiocchi C . Ulcerative colitis. N Engl J Med. 2011; 365(18):1713-25. DOI: 10.1056/NEJMra1102942. View

Rutgeerts P, Vermeire S, Van Assche G . Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut. 2007; 56(4):453-5. PMC: 1856849. DOI: 10.1136/gut.2005.088732. View

Colombel J, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y . Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011; 141(4):1194-201. DOI: 10.1053/j.gastro.2011.06.054. View

Mason M, Siegel C . Do inflammatory bowel disease therapies cause cancer?. Inflamm Bowel Dis. 2013; 19(6):1306-21. DOI: 10.1097/MIB.0b013e3182807618. View

Probert C, Hearing S, Schreiber S, Kuhbacher T, Ghosh S, Arnott I . Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003; 52(7):998-1002. PMC: 1773722. DOI: 10.1136/gut.52.7.998. View

10.

Froslie K, Jahnsen J, Moum B, Vatn M . Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133(2):412-22. DOI: 10.1053/j.gastro.2007.05.051. View

11.

Sands B, Kaplan G . The role of TNFalpha in ulcerative colitis. J Clin Pharmacol. 2007; 47(8):930-41. DOI: 10.1177/0091270007301623. View

12.

Nielsen O, Gionchetti P, Ainsworth M, Vainer B, Campieri M, Borregaard N . Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol. 1999; 94(10):2923-8. DOI: 10.1111/j.1572-0241.1999.01439.x. View

13.

Reinisch W, Sandborn W, Hommes D, DHaens G, Hanauer S, Schreiber S . Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60(6):780-7. DOI: 10.1136/gut.2010.221127. View

14.

Van Assche G, Rutgeerts P . Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005; 288(2):G169-74. DOI: 10.1152/ajpgi.00423.2004. View

15.

Lowenberg M, DHaens G . Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep. 2013; 15(2):311. DOI: 10.1007/s11894-012-0311-3. View

16.

Sandborn W, Van Assche G, Reinisch W, Colombel J, DHaens G, Wolf D . Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2011; 142(2):257-65.e1-3. DOI: 10.1053/j.gastro.2011.10.032. View

17.

Hoentjen F, van Bodegraven A . Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol. 2009; 15(17):2067-73. PMC: 2678575. DOI: 10.3748/wjg.15.2067. View

18.

Rahier J, Ben-Horin S, Chowers Y, Conlon C, De Munter P, DHaens G . European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2010; 3(2):47-91. DOI: 10.1016/j.crohns.2009.02.010. View

19.

Gornet J, Couve S, Hassani Z, Delchier J, Marteau P, Cosnes J . Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2003; 18(2):175-81. DOI: 10.1046/j.1365-2036.2003.01686.x. View

20.

Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C . Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128(7):1805-11. DOI: 10.1053/j.gastro.2005.03.003. View